All Episodes
VJHemOnc Podcast — 202 episodes
Advances in gene-based therapies for SCD and thalassemia: access, outcomes & innovation
The evolving role of BTK inhibitors in CLL
Advances in stem cell transplantation from EBMT 2026: managing GvHD, donor selection & evolving clinical strategies
Myeloid Monthly: breaking news & updates from the classification advancement meeting
How AI is transforming hematologic oncology
MRD in ALL and AML: from prognostic marker to clinical endpoint
Nursing in CAR-T & cellular therapy: updates and insights from the EBMT-EHA CAR T-cell Meeting 2026
Recent BTK inhibitor trial updates across non-Hodgkin lymphoma subtypes
ASH 2025 highlights in AL amyloidosis: risk stratification, bispecific antibodies, CAR-T, & MRD
Top ASH 2025 updates in AML: redefining frontline therapy, menin inhibition, venetoclax-based triplets, & emerging immunotherapies
Managing and preventing differentiation syndrome in APL
Top ASH 2025 NHL updates: novel CAR T-cell therapies, fixed-duration strategies, evolving frontline approaches, & more
Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T, trispecific antibodies, and more!
Top CLL updates from ASH 2025: novel BTKi monotherapy and combination approaches, BTK degraders, & more
Top updates in MDS from ASH 2025: key trial updates and debated topics
Sickle cell disease management: navigating the transition from pediatric to adult care, managing VOCs, & more
Accelerated- and blast-phase MPNs: diagnosis, management, and current challenges
The value and utility of MRD in the management of adults with newly-diagnosed AML
Updates from iwHRMM: targeted and immune-related therapies and mechanisms of resistance
Advances in immunotherapy for NHL: updates from iwNHL 2025
Reviewing recent guideline updates on the risk stratification and treatment of AML
The management of CLL in resource-limited settings: guideline development and ongoing projects
The multi-disciplinary team in CAR-T therapy: insights from a nurse, a neurologist, and a palliative care specialist
Understanding financial and time toxicity in cancer care: advice for community oncologists
Listener Q&A special: expert insights on CLL, myeloma, and lymphoma
Novel strategies and advances in the management and classification of MDS: insights from iwMDS 2025
Advances in Waldenström’s macroglobulinemia: significance of genetic alterations, current treatment strategies, & ongoing trials
FLT3-ITD+ AML: recent trial updates, novel approaches, and MRD
Extramedullary disease in multiple myeloma: biology, management strategies, & the RedirecTT-1 trial
iwMPN 2025 highlights: novel approaches to the upfront management of myelofibrosis, cardiovascular health in MPNs, & more
Managing CNS lymphoma: expert insights and updates from ICML 2025
iwMDS wrap-up: translating research into practice to optimize patient care
Targeting mutant CALR in MPNs with antibodies & cellular therapy: the potential for disease modification
Treating elderly or unfit patients with AML: current approach and future directions
Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more!
CHIP & CCUS: advances in understanding and should we treat these precursor conditions?
Diagnosing amyloidosis: identifying early signs, appropriate diagnostic tests, and challenges that remain
IPIG 2025 Highlights: challenging situations in PNH, updates from the COMMODORE trials, and more
Recent advances in Hodgkin lymphoma treatment: novel regimens, ongoing trials & treating R/R disease
Gene therapy in sickle cell disease: patient selection, potential complications, & more
Highlights from iwCAR-T 2025: improving the efficacy and safety of CAR T-cells & access in the community
Updates to the ESMO CLL clinical practice guidelines and implications for relapsed therapy
Highlights from iwMyeloma 2025: trial updates and practical considerations
Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment
Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more
Sequencing therapies in R/R NHL: immunotherapy in DLBCL, BTKis in MCL, & more!
Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms
Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more!
Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance
Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more!
CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes
Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more!
Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia
Post-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025
Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML
Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more!
Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting
Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS
Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more!
Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents
Improving care for patients with SCD: pain management, ongoing projects & unmet needs
Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment, & multidisciplinary care
Managing complications associated with WM: Bing-Neel syndrome, acquired von Willebrand disease, & more!
CAR-T therapies and bispecific antibodies in the treatment of high-risk multiple myeloma: updates from iwHRMM 2024
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events
An update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more!
CAR T-cells and bispecific antibodies in the treatment of NHL: updates from iwNHL 2024
Prolonging remission in AML: current approaches & future outlooks
A focus on the use of artificial intelligence to personalize blood cancer care
A focus on pediatric leukemias: trials, treatments, & challenges
A focus on the psychosocial impacts of living with blood cancer
Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more
Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges
Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more
Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024
Novel developments in lower-risk MDS & important practical considerations when treating patients
Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
Updates, challenges and novel agents being explored in BPDCN
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
iwNHL 2023 Session V: Expanding the CAR platform in NHL
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL
MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma
iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma
iwAL 2023 Session IV: transplantation and immunotherapies in AML: improving patient outcomes
Classifying frailty and approaching elderly patients with lymphoma
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
iwAL 2023 Session III: The relevance of TP53 mutation in AML
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions
Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
Overcoming barriers to CAR-T therapy: improving access and cost
The importance of addressing quality of life and improving symptom management in MPNs
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
Hemophilia: the current standard of care and the value of novel gene therapies
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes
iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks
iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies
iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed
The current role of stem cell transplantation in MPNs & how this may change with novel agents
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies
iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma
The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD
Insights into the changing role of chemotherapy in lymphoma
Comparing the ICC and WHO classifications for MDS and their impact on clinical practice
Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
The current status of CAR-T therapy in CLL and challenges in this space
Managing and treating GvHD and other post-transplant complications
The role of MRD in multiple myeloma
Novel immune therapies in MDS and challenges in this space
NHL highlights at ASH 2022: Updates in MCL, the role of transplantation, and novel bispecific antibodies
MPN highlights at ASH 2022: Novel agents, combinations & the role of immunotherapy
T-cell lymphoma highlights at ASH 2022: Unmet needs, clinical trial updates & future outlooks
The importance of CD47 in MDS and other targets of interest
CLL highlights at ASH 2022: Clinical trial updates, novel BTK inhibitors & combination therapy
Myeloma highlights at ASH 2022: Improving access to CAR-T therapy & future outlooks
Highlights in MDS at ASH 2022: Treating lower-risk & higher-risk disease, trial updates, & more
iwNHL Session V: Novel therapies in NHL - the role of ADCs
iwAL 2022 Session V: Mechanisms of resistance to targeted therapies in AML
The importance of genomic testing in CLL and its role in clinical decision-making
iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells
Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more
iwAL 2022 Session IV: The evolving treatment landscape in ALL and the growing role of immunotherapies
iwNHL Session III: Exploring the optimal management of R/R follicular lymphoma in an expanding treatment landscape
iwAL 2022 Session III: Novel targets, combinations and treatment strategies in AML
Recent updates in CML: treatment strategies, clinical trials, and novel agents
iwNHL Session II: Understanding and harnessing the immune microenvironment against lymphoma
iwAL 2022 Session II: Novel treatment strategies in ALL
The role of the innate immune system in MDS
iwAL 2022 Session I: The standard of care in AML in 2022
iwNHL 2022 Session I: Advances in the treatment of T-cell lymphoma
ISA 2022: meeting highlights and recent updates in amyloidosis
Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD
Highlights from the 2022 Texas MPN Workshop: early intervention, disease progression & future targets
iwMDS 2022: Key highlights
Identifying high-risk myeloma and improving treatment strategies in these patients
Improving the efficiency of drug approvals in MDS
Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment
The need for more effective first-line therapies in MDS
Myeloma 2022: day two highlights
The promise of CAR-T therapy in CLL and challenges in the field
Clonal hematopoiesis and pre-MDS states
T-cell engagers in multiple myeloma: current challenges and future outlooks
High-risk MDS: unmet needs and future treatment approaches
The importance of patient-reported outcomes in CAR-T recipients
CAR-T therapy in myeloma and lymphoma
CAR-T therapy in AML: challenges and future outlooks
The current state of CAR-T therapy in lymphoma
Myeloma treatment updates from EHA 2022
Updates in classification and risk stratification in MDS
Myeloma 2022: day one highlights
Immune dysregulation and targeting in MDS
The future of CAR-T therapy in ALL
An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs
Key updates in the treatment and management of MPNs
Addressing unmet needs and future treatment approaches in AL amyloidosis
Myeloma treatment in the UK: updates from Muk Nine b: OPTIMUM & the importance of genomics
Updates in lymphoma and CLL treatment in the UK
The importance of early intervention and interception in myeloma
Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline
CAR-T and lymphoma treatment in the UK
Harnessing the power of immunotherapy in myeloma and amyloidosis
The impact of AI and machine learning algorithms in MDS